Can-Fite BioPharma First Half 2024 Earnings: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma (TLV:CANF) First Half 2024 Results

Key Financial Results

• Revenue: US$316.0k (down 19% from 1H 2023).
• Net loss: US$3.96m (loss narrowed by 6.2% from 1H 2023).
• US$0.002 loss per share (improved from US$0.004 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Can-Fite BioPharma Earnings Insights

Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Asia.

Performance of the market in Israel.

The company's shares are down 3.3% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 6 warning signs for Can-Fite BioPharma (2 can't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.